The solution should appear clear and colorless to slightly yellow
Actual data from actual clinical trials, broken down so you can compare semaglutide and tirzepatide side by side and make a decision grounded in evidence rather than anxiety
Wegovy is approved for chronic weight management in obese and overweight individuals with at least one weight-related condition, such as type 2 diabetes mellitus, high blood pressure, and dyslipidemia
Within a year of treatment, many individuals achieve their weight loss and health goals, and they tend to have better long-term success in maintaining their results compared to those who have not used semaglutide GLP-1
Marketed under the brand name Wegovy, the tablet is authorized for chronic weight management in adults with obesity or who are overweight and also have at least one related health condition
This varies by insurance plan and pharmacy